Treatment of multifocal motor neuropathy

Madhavi Jinka, Vinay Chaudhry

Research output: Contribution to journalArticle

Abstract

Multifocalmotor neuropathy (MMN) is a treatable immune disorder of the peripheral nerves that is characterized clinically by slowly progressive or stepwise asymmetric distal 9 proximal, upper 9 lower limb weakness in multiple motor nerve distributions; electrophysiologically by multifocal motor demyelination, specifically partial motor conduction block; laboratory evidence of high serum anti-GM1 IgM antibodies; and remarkable treatment response to intravenous immunoglobulin (IVIG). IVIG has become the treatment of choice, and the U.S. Food and Drug Administration (FDA) has approved Gammagard Liquid 10 % [immune globulin infusion (human)] as a treatment for multifocal motor neuropathy (MMN). Response to IVIG inMMN is dose- and frequency-dependent,most patients needing high (2 g/kg) and frequent (every 4-8 weeks) doses for several years. Over time, response to IVIG may decrease despite higher and more frequent dosing of IVIG treatment. Subcutaneous immunoglobulin (dose equivalent to IVIG) given in weekly fashion has recently been used with equal efficacy and fewer side effects. There are some case reports and non-randomized trials suggesting variable results from therapeutic or adjunctive use of other immunosuppressive or immunomodulatory agents such as cyclophosphamide, cyclosporine, methotrexate, azathioprine, interferon beta-1a, and rituximab. Of these, cyclophosphamide and rituximab are the only immune treatments that have shown some benefits in case reports. One randomized controlled trial of mycophenolate mofetil used as adjunctive agent did not prove efficacious in altering the disease course. Although MMN, like chronic inflammatory demyelinating polyneuropathy (CIDP), is a chronic immune- mediated demyelinating neuropathy, the use of corticosteroids and plasma exchange - two other therapies used in CIDP - is not beneficial for MMN. Further investigations are warranted to evaluate the immunopathogenesis of MMN and to explore options for dose, frequency, and duration of IVIG treatment as well as the use of alternative immunomodulatory agents either as primary therapeutic or adjunctive agents.

Original languageEnglish (US)
Article number269
JournalCurrent Treatment Options in Neurology
Volume16
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Intravenous Immunoglobulins
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Therapeutics
Cyclophosphamide
Immunoglobulins
Mycophenolic Acid
Plasma Exchange
Immune System Diseases
Azathioprine
Demyelinating Diseases
United States Food and Drug Administration
Immunosuppressive Agents
Peripheral Nerves
Methotrexate
Cyclosporine
Lower Extremity
Adrenal Cortex Hormones
Randomized Controlled Trials
Antibodies
Serum

Keywords

  • Anti-GM1 antibody
  • Demyelination
  • Immune-mediated demyelinating neuropathy
  • Immunomodulatory agents
  • Immunosuppressive agents
  • IVIG
  • MMN
  • MMN treatment
  • Multifocal motor neuropathy
  • Partial motor conduction block
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Treatment of multifocal motor neuropathy. / Jinka, Madhavi; Chaudhry, Vinay.

In: Current Treatment Options in Neurology, Vol. 16, No. 2, 269, 02.2014.

Research output: Contribution to journalArticle

@article{4000c519bead4575b4f1f4f57d86528e,
title = "Treatment of multifocal motor neuropathy",
abstract = "Multifocalmotor neuropathy (MMN) is a treatable immune disorder of the peripheral nerves that is characterized clinically by slowly progressive or stepwise asymmetric distal 9 proximal, upper 9 lower limb weakness in multiple motor nerve distributions; electrophysiologically by multifocal motor demyelination, specifically partial motor conduction block; laboratory evidence of high serum anti-GM1 IgM antibodies; and remarkable treatment response to intravenous immunoglobulin (IVIG). IVIG has become the treatment of choice, and the U.S. Food and Drug Administration (FDA) has approved Gammagard Liquid 10 {\%} [immune globulin infusion (human)] as a treatment for multifocal motor neuropathy (MMN). Response to IVIG inMMN is dose- and frequency-dependent,most patients needing high (2 g/kg) and frequent (every 4-8 weeks) doses for several years. Over time, response to IVIG may decrease despite higher and more frequent dosing of IVIG treatment. Subcutaneous immunoglobulin (dose equivalent to IVIG) given in weekly fashion has recently been used with equal efficacy and fewer side effects. There are some case reports and non-randomized trials suggesting variable results from therapeutic or adjunctive use of other immunosuppressive or immunomodulatory agents such as cyclophosphamide, cyclosporine, methotrexate, azathioprine, interferon beta-1a, and rituximab. Of these, cyclophosphamide and rituximab are the only immune treatments that have shown some benefits in case reports. One randomized controlled trial of mycophenolate mofetil used as adjunctive agent did not prove efficacious in altering the disease course. Although MMN, like chronic inflammatory demyelinating polyneuropathy (CIDP), is a chronic immune- mediated demyelinating neuropathy, the use of corticosteroids and plasma exchange - two other therapies used in CIDP - is not beneficial for MMN. Further investigations are warranted to evaluate the immunopathogenesis of MMN and to explore options for dose, frequency, and duration of IVIG treatment as well as the use of alternative immunomodulatory agents either as primary therapeutic or adjunctive agents.",
keywords = "Anti-GM1 antibody, Demyelination, Immune-mediated demyelinating neuropathy, Immunomodulatory agents, Immunosuppressive agents, IVIG, MMN, MMN treatment, Multifocal motor neuropathy, Partial motor conduction block, Treatment",
author = "Madhavi Jinka and Vinay Chaudhry",
year = "2014",
month = "2",
doi = "10.1007/s11940-013-0269-y",
language = "English (US)",
volume = "16",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of multifocal motor neuropathy

AU - Jinka, Madhavi

AU - Chaudhry, Vinay

PY - 2014/2

Y1 - 2014/2

N2 - Multifocalmotor neuropathy (MMN) is a treatable immune disorder of the peripheral nerves that is characterized clinically by slowly progressive or stepwise asymmetric distal 9 proximal, upper 9 lower limb weakness in multiple motor nerve distributions; electrophysiologically by multifocal motor demyelination, specifically partial motor conduction block; laboratory evidence of high serum anti-GM1 IgM antibodies; and remarkable treatment response to intravenous immunoglobulin (IVIG). IVIG has become the treatment of choice, and the U.S. Food and Drug Administration (FDA) has approved Gammagard Liquid 10 % [immune globulin infusion (human)] as a treatment for multifocal motor neuropathy (MMN). Response to IVIG inMMN is dose- and frequency-dependent,most patients needing high (2 g/kg) and frequent (every 4-8 weeks) doses for several years. Over time, response to IVIG may decrease despite higher and more frequent dosing of IVIG treatment. Subcutaneous immunoglobulin (dose equivalent to IVIG) given in weekly fashion has recently been used with equal efficacy and fewer side effects. There are some case reports and non-randomized trials suggesting variable results from therapeutic or adjunctive use of other immunosuppressive or immunomodulatory agents such as cyclophosphamide, cyclosporine, methotrexate, azathioprine, interferon beta-1a, and rituximab. Of these, cyclophosphamide and rituximab are the only immune treatments that have shown some benefits in case reports. One randomized controlled trial of mycophenolate mofetil used as adjunctive agent did not prove efficacious in altering the disease course. Although MMN, like chronic inflammatory demyelinating polyneuropathy (CIDP), is a chronic immune- mediated demyelinating neuropathy, the use of corticosteroids and plasma exchange - two other therapies used in CIDP - is not beneficial for MMN. Further investigations are warranted to evaluate the immunopathogenesis of MMN and to explore options for dose, frequency, and duration of IVIG treatment as well as the use of alternative immunomodulatory agents either as primary therapeutic or adjunctive agents.

AB - Multifocalmotor neuropathy (MMN) is a treatable immune disorder of the peripheral nerves that is characterized clinically by slowly progressive or stepwise asymmetric distal 9 proximal, upper 9 lower limb weakness in multiple motor nerve distributions; electrophysiologically by multifocal motor demyelination, specifically partial motor conduction block; laboratory evidence of high serum anti-GM1 IgM antibodies; and remarkable treatment response to intravenous immunoglobulin (IVIG). IVIG has become the treatment of choice, and the U.S. Food and Drug Administration (FDA) has approved Gammagard Liquid 10 % [immune globulin infusion (human)] as a treatment for multifocal motor neuropathy (MMN). Response to IVIG inMMN is dose- and frequency-dependent,most patients needing high (2 g/kg) and frequent (every 4-8 weeks) doses for several years. Over time, response to IVIG may decrease despite higher and more frequent dosing of IVIG treatment. Subcutaneous immunoglobulin (dose equivalent to IVIG) given in weekly fashion has recently been used with equal efficacy and fewer side effects. There are some case reports and non-randomized trials suggesting variable results from therapeutic or adjunctive use of other immunosuppressive or immunomodulatory agents such as cyclophosphamide, cyclosporine, methotrexate, azathioprine, interferon beta-1a, and rituximab. Of these, cyclophosphamide and rituximab are the only immune treatments that have shown some benefits in case reports. One randomized controlled trial of mycophenolate mofetil used as adjunctive agent did not prove efficacious in altering the disease course. Although MMN, like chronic inflammatory demyelinating polyneuropathy (CIDP), is a chronic immune- mediated demyelinating neuropathy, the use of corticosteroids and plasma exchange - two other therapies used in CIDP - is not beneficial for MMN. Further investigations are warranted to evaluate the immunopathogenesis of MMN and to explore options for dose, frequency, and duration of IVIG treatment as well as the use of alternative immunomodulatory agents either as primary therapeutic or adjunctive agents.

KW - Anti-GM1 antibody

KW - Demyelination

KW - Immune-mediated demyelinating neuropathy

KW - Immunomodulatory agents

KW - Immunosuppressive agents

KW - IVIG

KW - MMN

KW - MMN treatment

KW - Multifocal motor neuropathy

KW - Partial motor conduction block

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84891506795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891506795&partnerID=8YFLogxK

U2 - 10.1007/s11940-013-0269-y

DO - 10.1007/s11940-013-0269-y

M3 - Article

C2 - 24395647

AN - SCOPUS:84891506795

VL - 16

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 2

M1 - 269

ER -